Disorders Due to Use of Sedatives, Hypnotics or Anxiolytics (ICD-11: 6C44)

1. Introduction

Disorders due to the use of sedatives, hypnotics, or anxiolytics represent a growing challenge for health systems worldwide. These substances, frequently prescribed for legitimate treatment of anxiety, insomnia, and other medical conditions, possess dependency-inducing properties that can lead to problematic patterns of use when employed for prolonged periods or at doses higher than recommended.

The clinical importance of these disorders lies in the fact that many patients initiate the use of these medications under medical supervision, but gradually develop physical and psychological dependence. Benzodiazepines, "Z-drugs" (zolpidem, zopiclone, zaleplon), and, to a lesser extent currently, barbiturates, constitute the main classes involved. The transition from therapeutic use to problematic use can be subtle and progressive, making early identification fundamental.

The impact on public health is significant, considering that these substances are among the most prescribed psychotropic medications worldwide. Beyond the risks of dependence, prolonged use is associated with cognitive impairment, increased risk of falls and fractures, traffic accidents, and potentially fatal drug interactions, especially when combined with alcohol or opioids.

Correct coding using ICD-11 is critical for establishing precise prevalence, allocating adequate resources, monitoring epidemiological trends, and ensuring that patients receive appropriate treatment. Adequate documentation also enables longitudinal tracking of cases and evaluation of the effectiveness of implemented interventions.

2. Correct ICD-11 Code

Code: 6C44

Description: Disorders due to use of sedatives, hypnotics or anxiolytics

Parent category: Disorders due to substance use

Official definition: Disorders due to use of sedatives, hypnotics or anxiolytics are characterized by the pattern and consequences of use of these substances. Sedatives, hypnotics and anxiolytics are typically prescribed for short-term treatment of anxiety or insomnia, and are also employed in sedation for medical procedures. They include benzodiazepines and positive allosteric modulators of non-benzodiazepine GABA receptors (i.e., "Z drugs"), as well as many other compounds.

Sedatives, hypnotics and anxiolytics include barbiturates, which are now much less available than in previous decades. These substances have dose- and duration-related dependence-inducing properties. They can cause intoxication, dependence and withdrawal. Various other mental disorders induced by sedatives, hypnotics and anxiolytics are recognized.

This code encompasses the full spectrum of disorders related to use of these substances, from single episodes of intoxication to established patterns of dependence and withdrawal-related complications.

3. When to Use This Code

The code 6C44 should be applied in specific clinical scenarios where there is clear evidence of a disorder related to the use of sedatives, hypnotics, or anxiolytics:

Scenario 1: Dependence developed after medical prescription A 58-year-old patient who initiated benzodiazepine use for insomnia treatment three years ago. Currently uses progressively higher doses, experiences intense anxiety when attempting to reduce medication, and presents with recent memory impairment. Seeks multiple physicians to obtain additional prescriptions. Criteria present: continued use despite negative consequences, tolerance, withdrawal symptoms when attempting to discontinue.

Scenario 2: Acute intoxication requiring medical care An individual presents to the emergency department with extreme drowsiness, slurred speech, ataxia, and mental confusion following excessive ingestion of alprazolam. Toxicological examination confirms elevated benzodiazepine levels. The code is appropriate for documenting the episode of acute sedative intoxication.

Scenario 3: Withdrawal syndrome A hospitalized patient admitted for another reason who had been using clonazepam daily for two years develops tremors, profuse diaphoresis, psychomotor agitation, severe insomnia, and seizures 48 hours after admission when the medication was not continued. Benzodiazepine withdrawal syndrome constitutes a clear indication for use of this code.

Scenario 4: Problematic use of "Z-drugs" A person who initiated zolpidem for insomnia 18 months ago, now uses doses higher than prescribed, exhibits complex sleep behaviors (eating, driving without subsequent recall), and is unable to sleep without the medication. Manifests excessive concern in ensuring continuous supply of the substance.

Scenario 5: Concomitant use with other substances A patient with a history of alcohol use who also uses diazepam in a non-prescribed manner to "control anxiety" and "potentiate relaxing effects." Presents with significant impairment of occupational and social functioning. The code 6C44 is used specifically for the component related to benzodiazepines.

Scenario 6: Substance-induced mental disorder An individual develops a significant depressive condition temporally related to chronic use of sedative-hypnotics, with symptoms exceeding what would be expected for intoxication or withdrawal. The code 6C44 documents the mental disorder induced by these substances.

4. When NOT to Use This Code

It is essential to recognize situations where code 6C44 is not appropriate:

Hazardous use without dependence: If the patient presents a pattern of use that puts their health at risk, but does not meet criteria for dependence, intoxication, or other specific disorders, the correct code is [QE11.4](/en/code/QE11.4) (Hazardous use of sedatives, hypnotics or anxiolytics). Example: person who occasionally combines benzodiazepines with alcohol in social situations, but does not present dependence or regular use.

Appropriate therapeutic use: Patient using benzodiazepines as prescribed by a physician, in adequate doses, for a limited period, without development of tolerance, dependence, or negative consequences. In this case, there is no disorder to be coded, only treatment of the underlying condition.

Adverse effects unrelated to use disorder: Idiosyncratic adverse reactions or expected side effects of therapeutic use (such as daytime drowsiness at therapeutic doses) should be coded as adverse effects of medications, not as use disorder.

Accidental intoxication in children: Accidental ingestion of sedatives by a small child should be coded as accidental intoxication, not as use disorder, using appropriate poisoning codes.

Primary anxiety or sleep disorders: The primary diagnosis of anxiety disorder or insomnia should not be confused with sedative use disorder. Prescription and appropriate use of these medications to treat legitimate conditions does not constitute use disorder, unless a subsequent problematic pattern develops.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Confirmation of diagnosis requires systematic evaluation of multiple domains. Begin with detailed history of use pattern: when it started, initial versus current dose, frequency, route of administration, and circumstances of use. Investigate whether there was dose escalation, use for longer periods than intended, and unsuccessful attempts to reduce or control use.

Assess negative consequences: cognitive impairment, accidents, interpersonal or occupational problems related to use. Question about tolerance (need for larger doses for the same effect) and withdrawal symptoms when there is reduction or discontinuation.

Useful instruments include the ASSIST (Alcohol, Smoking and Substance Involvement Screening Test), specific questionnaires for benzodiazepine dependence, and neuropsychological evaluation when cognitive impairment is suspected. Toxicological tests can confirm recent use, but do not establish disorder diagnosis by themselves.

Step 2: Verify specifiers

Determine whether there is a single episode (isolated intoxication) or a pattern of continuous or episodic use. For dependence, assess severity considering number of criteria met and degree of functional impairment.

Identify whether there is remission (sustained or in a protected environment) and for how long. Document presence of current or past withdrawal syndrome, including severity (mild, moderate, severe, with complications such as seizures).

Record whether there are specific induced mental disorders: delirium, psychotic disorder, mood disorder, anxiety disorder, or other disorders induced by sedative-hypnotics.

Step 3: Differentiate from other codes

6C40 (Disorders due to use of alcohol): The key difference is the primary substance of use. Although there may be concomitant use, code 6C44 is specific for sedatives, hypnotics, and anxiolytics. Alcohol, despite also acting on the GABAergic system, has its own code. In cases of multiple substance use, both codes may be applied.

6C41 (Disorders due to use of cannabis): Differentiated by completely distinct pharmacological class. Cannabis acts primarily on cannabinoid receptors, not on GABA receptors. The clinical presentation, intoxication pattern, and withdrawal syndrome are markedly different.

6C42 (Disorders due to use of synthetic cannabinoids): Similar to the previous code, but specific for synthetic substances that mimic cannabis. The distinction from 6C44 is based on completely different mechanism of action and chemical class.

Step 4: Required documentation

Checklist of mandatory information:

Specific substance used (generic and trade name)
Current daily dose and evolution over time
Total duration of use
Route of administration
Pattern of use (daily, episodic, binge)
Source of obtaining (prescription, multiple prescribers, illicit market)
Presence and severity of tolerance
Withdrawal symptoms (type, severity, duration)
Previous discontinuation attempts and their results
Medical, psychological, social, and occupational consequences
Concomitant use of other substances
Previous treatments and response
Psychiatric and medical comorbidities

The record should include mental status evaluation, relevant physical examination (signs of intoxication or withdrawal), results of laboratory and toxicological tests, and risk assessment (suicide, accidents, serious medical complications).

6. Complete Practical Example

Clinical Case:

Maria, 52 years old, teacher, presents to psychiatric consultation referred by her family physician. She reports that five years ago she started using clonazepam 0.5mg at night for insomnia related to a period of work stress. Initially the medication was effective, but after six months she began waking during the night. Her physician increased the dose to 1mg.

Over the following years, Maria gradually increased the dose on her own, currently using 4mg per day (2mg in the morning, 2mg at night). She reports that she "cannot function" without the medication, presenting with intense anxiety, tremors, and palpitations when she delays a dose. She attempted to reduce the medication three times in the last year, but on all occasions developed severe insomnia, extreme agitation, and on the last attempt, had a seizure.

Maria notes increasing memory difficulties, forgetting appointments and recent conversations. Her work performance has deteriorated, with difficulty concentrating during classes. She seeks two different physicians to obtain prescriptions, worried about "never running out of" the medication. She denies alcohol or other substance use.

On examination: patient alert, oriented, but visibly anxious. Speech slightly slurred. Mini-mental state examination reveals recent memory deficits. Mild tremor of extremities. Vital signs normal.

Step-by-Step Coding:

Criteria Analysis:

Pattern of problematic use: Use for a period much longer than recommended (five years versus 2-4 weeks indicated), significant dose escalation (0.5mg to 4mg daily), use not in accordance with prescription.
Impaired control: Unsuccessful attempts to reduce use, persistent concern about maintaining supply, seeking multiple prescribers.
Tolerance: Need for progressively larger doses to obtain the effect initially achieved with smaller doses.
Withdrawal: Clear withdrawal symptoms (anxiety, tremors, palpitations, insomnia, agitation, seizure) when there is reduction or delay in dose.
Negative consequences: Cognitive impairment (memory deficits), occupational impairment (work performance), medical risk (seizure during discontinuation attempt).
Continued use despite consequences: Continues using despite recognizing memory problems and professional difficulties.

Code selected: 6C44 - Disorders due to use of sedatives, hypnotics or anxiolytics

Complete Justification:

Maria meets clear criteria for benzodiazepine dependence (clonazepam). The pattern of use evolved from therapeutic to problematic, with development of tolerance, physical dependence evidenced by withdrawal syndrome (including seizure, which represents severe withdrawal), functional impairment, and loss of control over use.

The presence of multiple criteria (dose escalation, prolonged use, unsuccessful discontinuation attempts, withdrawal symptoms, tolerance, negative consequences, continued use despite harm) establishes a diagnosis of moderate to severe dependence.

Applicable Complementary Codes:

Additional code for withdrawal syndrome with complications (seizure)
Code for sedative-induced cognitive impairment if formal neuropsychological evaluation confirms significant deficits
Code for the condition that originated the initial prescription, if still present

7. Related Codes and Differentiation

Within the Same Category:

6C40: Disorders due to use of alcohol

When to use 6C40: When the primary substance of abuse is alcohol (ethanol), regardless of the form of consumption (beer, wine, spirits). Even if the patient also uses sedatives occasionally, if alcohol is the predominant and problematic substance, 6C40 is the primary code.

Main difference: The substance in question. Alcohol has a distinct pharmacological profile, intoxication pattern, and withdrawal syndrome, although both act on the GABAergic system. Alcohol causes specific hepatic damage (cirrhosis), while benzodiazepines have greater association with cognitive impairment. In significant concurrent use of both substances, both codes may be applied.

6C41: Disorders due to use of cannabis

When to use 6C41: When the problematic pattern involves cannabis (marijuana, hashish, cannabis oils), with regular use, development of tolerance, withdrawal symptoms (irritability, insomnia, decreased appetite), or negative consequences specifically related to cannabis use.

Main difference: Cannabis acts on cannabinoid receptors (CB1 and CB2), not on GABA receptors. The intoxication profile includes euphoria, alterations in time perception, red eyes, and increased appetite—very different from the sedation and motor impairment of benzodiazepines. Cannabis withdrawal syndrome is generally milder and does not include risk of seizures.

6C42: Disorders due to use of synthetic cannabinoids

When to use 6C42: Specific to synthetic substances that mimic cannabis effects (known as "spice," "K2," and other commercial names), but with potency often greater and more unpredictable effects than natural cannabis.

Main difference: Although the mechanism of action is similar to cannabis (cannabinoid receptors), synthetics have a worse safety profile, with greater risk of psychosis, seizures, and other serious complications. Completely distinct from sedative-hypnotics in terms of pharmacology, clinical presentation, and specific risks.

Differential Diagnoses:

Primary anxiety disorders: Patients with generalized anxiety disorder, panic disorder, or social phobia may use benzodiazepines therapeutically without developing use disorder. The distinction requires assessing whether there is use as prescribed, absence of dose escalation, and whether anxiety symptoms precede and are independent of medication use.

Primary insomnia: Appropriate use of hypnotics for insomnia, as medically directed and for a limited period, does not constitute use disorder. It is differentiated by the absence of loss of control, dose escalation, or negative consequences beyond expected side effects.

Neurocognitive disorders: Cognitive deficits in older adults may be erroneously attributed to benzodiazepine use when they actually represent primary dementia. Longitudinal history and neuropsychological evaluation aid in differentiation.

8. Differences with ICD-10

In ICD-10, disorders related to the use of sedatives and hypnotics were coded primarily as F13 (Mental and behavioral disorders due to use of sedatives or hypnotics), with subdivisions for acute intoxication (F13.0), harmful use (F13.1), dependence syndrome (F13.2), withdrawal syndrome (F13.3), and other conditions.

Main changes in ICD-11:

ICD-11 introduces greater specificity and conceptual clarity. Code 6C44 encompasses the entire spectrum of disorders related to these substances in a more integrated manner, with better distinction between hazardous use (which does not constitute dependence) and established disorders.

Terminology has been updated, abandoning terms such as "harmful use" in favor of "hazardous use" and "disorders due to use". There is greater emphasis on the dimensional characterization of severity and explicit recognition of mental disorders induced by these substances.

ICD-11 also offers better alignment with contemporary diagnostic criteria, facilitating clinical application and research. The hierarchical structure is clearer, allowing more precise coding of specific presentations.

Practical impact: Professionals familiar with F13 from ICD-10 will need to adapt to the new system, but will find greater conceptual clarity and clinical utility. The transition requires training and updating of electronic health record systems, but results in more accurate and useful documentation for treatment and research.

9. Frequently Asked Questions

How is the diagnosis of disorders due to the use of sedatives, hypnotics or anxiolytics made?

The diagnosis is primarily clinical, based on detailed history and mental status examination. The pattern of use (dose, frequency, duration), presence of tolerance and withdrawal symptoms, attempts to control use, and negative consequences are investigated. Screening instruments such as ASSIST can be helpful. Toxicological tests confirm recent use, but do not establish a disorder diagnosis by themselves. Neuropsychological evaluation can be useful when cognitive impairment is suspected. The evaluation should be comprehensive, considering psychosocial context and comorbidities.

Is treatment available in public health systems?

In many countries, public health systems offer treatment for substance use disorders, including sedatives and hypnotics. Treatment typically includes supervised detoxification (essential to prevent serious withdrawal complications), cognitive-behavioral therapy, management of psychiatric comorbidities, and psychosocial support. Specific availability varies by region and local resources, but growing recognition of these disorders as serious medical conditions has expanded access to treatment in many contexts.

How long does treatment last?

Duration varies significantly depending on the severity of dependence, duration of use, dose used, and individual factors. Supervised detoxification generally requires 2-8 weeks of gradual dose reduction to minimize withdrawal symptoms and prevent complications. After detoxification, psychological treatment and support typically continue for 6-12 months or longer. Some patients benefit from long-term follow-up to prevent relapse. The process should not be rushed; abrupt discontinuation of benzodiazepines can be dangerous, causing seizures and other serious complications.

Can this code be used in medical certificates?

Yes, code 6C44 can be used in official medical documentation, including certificates when necessary. However, professionals should consider confidentiality and stigma issues. In many contexts, it is possible to provide certificates that document the need for leave without specifying the complete diagnosis, protecting patient privacy while providing adequate documentation for occupational or administrative purposes. The decision about the level of detail to include should balance documentation needs with privacy protection and stigma minimization.

What is the difference between physical and psychological dependence?

Physical dependence refers to physiological adaptation of the organism to the substance, manifested by tolerance (need for higher doses) and withdrawal (physical symptoms when discontinuation occurs). Psychological dependence involves compulsion to use, preoccupation with obtaining the substance, and use to cope with emotional states. In disorders related to sedative-hypnotics, both components typically coexist. Physical dependence is particularly significant with these substances, as withdrawal can be medically dangerous, requiring supervised management.

Is it possible to use benzodiazepines safely long-term?

Current medical consensus recommends benzodiazepine use only for short periods (2-4 weeks), due to the risk of dependence and other adverse effects. Prolonged use is associated with cognitive impairment, increased risk of falls, accidents, and dependence. In exceptional situations where prolonged use is considered, there should be rigorous monitoring, use of the lowest effective dose, regular evaluation of continued need, and periodic attempts at gradual reduction. Non-benzodiazepine alternatives should always be considered for long-term management of anxiety or insomnia.

What should be done if a patient has been using benzodiazepines for years?

Abrupt discontinuation should never be attempted due to the risk of seizures and other serious complications. Appropriate management involves: complete assessment of the pattern of use and severity of dependence; patient education about risks and benefits; development of a supervised gradual reduction plan (typically 10-25% of the dose every 1-2 weeks, adjusted according to tolerance); treatment of underlying psychiatric conditions; implementation of non-pharmacological strategies for anxiety and insomnia; psychological support during the process; and regular monitoring for withdrawal symptoms. The process requires patience, collaboration between professional and patient, and often multidisciplinary support.

What are the risks of combining sedatives with alcohol or opioids?

The combination of sedative-hypnotics with alcohol or opioids is extremely dangerous, potentially causing severe respiratory depression and death. All these substances depress the central nervous system, and their effects are synergistic, not merely additive. Even therapeutic doses of benzodiazepines combined with alcohol or opioids can result in profound sedation, respiratory compromise, coma, and death. Patients should be explicitly warned about these risks. In contexts of pain treatment with opioids, if benzodiazepines are absolutely necessary, rigorous monitoring and use of the lowest possible doses of both substances is required.

Conclusion:

The ICD-11 code 6C44 represents an essential tool for accurate documentation of disorders related to the use of sedatives, hypnotics, and anxiolytics. Correct application of this code requires understanding of diagnostic criteria, ability to differentiate from related conditions, and adequate documentation of the pattern of use and its consequences. Recognition and appropriate treatment of these disorders are fundamental to preventing serious complications and improving clinical outcomes, contributing to global public health through accurate epidemiological data and adequate allocation of resources for prevention and treatment.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Disorders due to the use of sedatives, hypnotics or anxiolytics

Partager